Noticias y eventos de Scribe Therapeutics Inc. Common Stock (SCTX)SCTXScribe Therapeutics Inc. Common Stock

Scribe Therapeutics Q2 Revenue $1.92M, Below Consensus

Reports Q2 revenue $1.92M, consensus $3.11M. "The second quarter and the weeks immediately following represented a transformational period for Scribe," said Benjamin Oakes, co-founder and CEO of Scribe Therapeutics. "We advanced our lead silencing asset STX-1150 into the clinic, secured significant grant support from CIRM to develop our next two cardiometabolic assets, and successfully completed our initial public offering. These achievements position us to execute across a broadly differentiated portfolio of CRISPR genetic medicines designed to address the three major lipid drivers of atherosclerotic cardiovascular disease: LDL-C, Lp(a), and triglycerides. Our purpose-built technologies are uniquely poised to democratize access to the cardioprotective effects of beneficial human genetics. Guided by nature's blueprint for improved cardiovascular health, our aim is to shift the treatment paradigm of heart disease from chronic intervention of symptoms toward durable disease prevention and lifespan extension."